Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13933856 | 0.84 | HCAR2 (0.49) | HCAR2CYP2C9 | |
| SCHEMBL4548409 | 0.81 | HCAR2 (0.64) | HCAR2CYP2C9 | |
| SCHEMBL14340940 | 0.81 | TP53 (0.54) | HCAR2CYP2C9 | |
| SCHEMBL4548432 | 0.80 | HCAR2 (0.49) | HCAR2 | |
| SCHEMBL4548464 | 0.80 | HCAR2 (0.66) | HCAR2CYP2C9 | |
| SCHEMBL4548429 | 0.79 | MAOB (0.46) | HCAR2 | |
| SCHEMBL4548335 | 0.79 | HCAR2 (1.00) | HCAR2CYP2C9 | |
| SCHEMBL4548428 | 0.78 | HCAR2 (0.66) | HCAR2CYP2C9 | |
| SCHEMBL4548471 | 0.73 | HCAR2 (0.70) | HCAR2CYP2C9 | |
| SCHEMBL4548407 | 0.72 | LMNA (0.52) | HCAR2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
| WO-2007002557-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | HCAR2 2/4885CYP2C9 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.